In melanoma, tumor regression based on the anti-tumor effects of an anti-PD-1 Ab requires the presence of CD8+ T-cells in the tumor [5] and activation of the β-catenin pathway in the tumor is inversely correlated with the extent of CD8+ T-cell infiltration [6]. This evidence concerns the gene PDCD1 and neoplasm.